Advertisement

Therapeutic tools in portal hypertension: drugs

  • Agustín Albillos
Conference paper

Abstract

Portal hypertension often complicates the course of chronic liver disease and is a principal cause of mortality. Improvements in treating this complication made towards the end of the past century have been the consequence of several major achievements in our understanding of the pathophysiology of portal hypertension:
  1. 1.

    Increased intrahepatic vascular resistance (IHVR) to portal blood flow is the factor that initiates portal hypertension, but increased splanchnic blood flow due to splanchnic vasodilation contributes to maintain and aggravate this portal hypertension. Based on this finding, splanchnic vasoconstrictors are currently used to treat portal hypertension. As do beta-blockers, these reduce portal pressure, decreasing splanchnic blood flow.

     
  2. 2.

    In the cirrhotic liver, increased IHVR is the result of fixed elements (i.e. extracellular matrix, regenerative nodules, and vascular thrombosis) and elements that can be modulated (i.e. endothelial and stellate cells)1. Although the resistance provided by each of these modulatable and fixed elements is difficult to quantify precisely, vasodilators can reduce portal resistance up to 15% in the perfused cirrhotic rat liver2. This drop represents about 30% of the difference in resistance between the cirrhotic and normal liver. The dynamic component of the IHVR is a consequence of an enhanced vascular tone, secondary to an imbalance between vasoconstrictor and vasodilatory stimuli. Recent evidence indicates that a deficient intrahepatic release of nitric oxide (NO) plays a key role in the hepatic endothelial dysfunction of cirrhosis3, 4. In the normal liver the sinusoidal endothelial cells basally produce NO and increase its production in response to flow5, 6. In contrast, the cirrhotic liver fails to produce NO in response to incremental flow7. Endothelial(e)-NO synthase (NOS) and protein levels are unaltered, but endothelial-derived NO is impaired6. Since eNOS is extensively modified at the post-translational level, deficient NO release could be the consequence of an abnormality in one of these biochemical modifications occurring after injury to sinusoidal endothelial cells. For example, caveolin-l controls eNOS activity, and increased binding of caveolin to eNOS in cirrhosis is associated with reduced eNOS activity7. In addition, protein kinase B (Akt) phosphorylates eNOS and enhances its ability to generate NO. Down-regulation of Akt activity is responsible, in part, for the diminished NO production observed in cirrhotic livers, and constitutes another potential target for restoring hepatic endothelial function8. The hepatic vascular tone of the cirrhotic liver is also influenced by an increased production and exaggerated response to vasoconstrictors, such as endothelin-19, angiotensin II10, norepinephrine11, 12, 13, 14, thromboxane and leukotrienes15, 16. Knowing that an increased intrahepatic vascular tone contributes toward increasing portal pressure has provided a rational basis for the use of vasodilators to treat portal hypertension.

     
  3. 3.

    The third important concept is the correlation between the value or change in portal pressure, as measured by the hepatic venous pressure gradient (HVPG), and clinical events (i.e. variceal formation and bleeding). Pharmacological or spontaneous reduction in portal pressure to below 12 mmHg, or more than 20% from baseline, leads to a null or low (10%) risk of variceal bleeding, respectively17, 18, 19, 20, 21, 22. Pharmacological treatment seeks to achieve this reduction in portal pressure since it is known that this will lessen the risk of variceal bleeding and other complications of cirrhosis23. Non-response to vasoactive therapy is the most important independent risk factor for variceal bleeding23.

     

Keywords

Nitric Oxide Portal Hypertension Variceal Bleeding Cirrhotic Liver Portal Pressure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    McCuskey RS. Morphological mechanisms for regulating blood flow through hepatic sinusoids. Liver. 2000;20:3–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol. 1985;1:325–37.PubMedCrossRefGoogle Scholar
  3. 3.
    Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation: effects on portal hemodynamics and on liver and renal function. Hepatology. 1998;28:926–31.PubMedCrossRefGoogle Scholar
  4. 4.
    Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology. 2002;35:478–91.PubMedCrossRefGoogle Scholar
  5. 5.
    Shah V, Haddad F, Garcia-Cardena G et al. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. J Clin Invest. 1997;100:2923–30.PubMedCrossRefGoogle Scholar
  6. 6.
    Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology. 1998;114:344–51.PubMedCrossRefGoogle Scholar
  7. 7.
    Shah V, Toruner M, Haddad F et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology. 1999;117: 1222–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Morales-Ruiz M, Cejudo-Martin P, Fernandez-Varo G et al. Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology. 2003;125:522–31.PubMedCrossRefGoogle Scholar
  9. 9.
    Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology. 1996;24:233–40.PubMedCrossRefGoogle Scholar
  10. 10.
    Bataller R, Gines P, Nicolas JM et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology. 2000;118:1149–56.PubMedCrossRefGoogle Scholar
  11. 11.
    Albillos A, Bañares R, Barrios C et al. Oral administration of c10nidine in patients with alcoholic cirrhosis: hemodynamic and liver function effects. Gastroenterology. 1992;102:248–54.PubMedGoogle Scholar
  12. 12.
    Albillos A, Lledo JL, Banares R et al. Hemodynamic effects of α-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension. Hepatology. 1994;20:611–17.PubMedGoogle Scholar
  13. 13.
    Albillos A, Lledo JL, Rossi I et al. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology. 1995;109:1257–65.PubMedCrossRefGoogle Scholar
  14. 14.
    Marteau P, Ballet F, Chazouilleres O et al. Effect of vasodilators on hepatic microcirculation in cirrhosis: a study in the isolated perfused rat liver. Hepatology. 1989;9:820–3.PubMedCrossRefGoogle Scholar
  15. 15.
    Titos E, Claria J, Bataller R et al. Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology. 2000;119:794–805.PubMedCrossRefGoogle Scholar
  16. 16.
    Graupera M, Garcia-Pagan JC, Titos E et al. 5-Lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. Gastroenterology. 2002;122:387–93.PubMedCrossRefGoogle Scholar
  17. 17.
    Groszmann RJ, Bosch J, Grace ND et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology. 1990;99:1401–7.PubMedGoogle Scholar
  18. 18.
    Feu F, Garcia-Pagan JC, Bosch J et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet. 1995;346:1056–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Merkel C, Bolognesi M, Sacerdoti D et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology. 2000;32:930–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Villanueva C, Balanzo J, Novella MT et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med. 1996;334:1624–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Villanueva C, Minana J, Ortiz J et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med. 2001;345:647–55.PubMedCrossRefGoogle Scholar
  22. 22.
    Bosch J, Arroyo V, Betriu A et al. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology. 1980;78:92–9.PubMedGoogle Scholar
  23. 23.
    Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch I. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003;37:902–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Garcia-Pagan JC, Feu F, Bosch I, Rodés J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med. 1991;114:869–73.PubMedGoogle Scholar
  25. 25.
    Albillos A, Garcia-Pagan JC, Iborra J et al. Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. Gastroenterology. 1998;115:116–23.PubMedCrossRefGoogle Scholar
  26. 26.
    Kroeger RJ, Groszmann RJ. Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agents in a portal hypertensive model. Hepatology. 1985;5:97–101.PubMedCrossRefGoogle Scholar
  27. 27.
    Escorsell A, Ferayorni L, Bosch J et al. The portal pressure response to beta-blockade is greater in cirrhotic patients without varices than in those with varices. Gastroenterology. 1997;112:2012–16.PubMedCrossRefGoogle Scholar
  28. 28.
    Albillos A, Pérez M, Cacho G, Calleja JL, Escartín P. Accuracy of portal and forearm blood flow measurements in the assessment of portal pressure response to propranolol. I Hepatol. 1997;27:496–504.CrossRefGoogle Scholar
  29. 29.
    Garcia-Tsao G, Grace ND, Groszmann RJ et al. Short-term effects of propranolol on portal venous pressure. Hepatology. 1986;6:101–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Gengo FM, Huntoon L, McHugh WB. Lipid-soluble and water-soluble beta-blockers. Comparison of the central nervous system depressant effect. Arch Intern Med. 1987;147: 39–43.PubMedCrossRefGoogle Scholar
  31. 31.
    Groszmann RJ, Garcia-Tsao G, Bosch J et al. Multicenter randomized placebo-controlled trial of non-selective beta-blockers in the prevention of the complications of portal hypertension: final results and identification of a predictive factor. Hepatology. 2003;38:206A.CrossRefGoogle Scholar
  32. 32.
    Groszmann RI, Kravetz D, Bosch J et al. Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension. Hepatology. 1982;2:757–62.PubMedCrossRefGoogle Scholar
  33. 33.
    Groszmann R. Beta-adrenergic blockers and nitro vasodilators for the treatment of portal hypertension: the good, the bad, the ugly. Gastroenterology. 1997;113:1794–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Harrison D, Bates J. The nitro vasodilators: new ideas about old drugs. Circulation. 1993;87:1461–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Garcia-Tsao G, Groszmann RJ. Portal hemodynamics during nitroglycerin administration in cirrhotic patients. Hepatology. 1987;7:805–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Navasa M, Chesta J, Bosch J, Rodes J. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function. Gastroenterology. 1989;96:1110–18.PubMedGoogle Scholar
  37. 37.
    Bellis L, Berzigotti A, Abraldes JG et al. Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology. 2003;37:378–84.PubMedCrossRefGoogle Scholar
  38. 38.
    Angelico M, Carli L, Piat C, Gentile S, Capocaccia L. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. Gastroenterology. 1997;113:1632–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Garcia-Pagan JC, Villanueva C, Vila MC et al. Isosorbide mononitratc in the prevention of first variceal bleed in patients who cannot receive beta-blockers. Gastroenterology. 2001;121:908–14.PubMedGoogle Scholar
  40. 40.
    Dudenhoefer AA, Loureiro-Silva MR, Cadelina GW, Gupta T, Groszmann RJ. Bioactivation of nitroglycerin and vasomotor response to nitric oxide are impaired in cirrhotic rat livers. Hepatology. 2002;36:381–5.PubMedCrossRefGoogle Scholar
  41. 41.
    Gournay J, Masliah C, Martin T, Perrin D, Galmiche JP. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology. 2000;31:1239–45.PubMedCrossRefGoogle Scholar
  42. 42.
    Garcia-Pagan JC, Morillas R, Banares R et al. Spanish Variceal Bleeding Study Group. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology. 2003;37:1260–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Fiorucci S, Antonelli E, Morelli O et al. NCX-l000, a NO-releasing derivative ofursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci USA. 2001;98:8897–902.PubMedCrossRefGoogle Scholar
  44. 44.
    Fiorucci S, Antonelli E, Brancaleone V et al. NCX-l000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. J Hepatol. 2003;39:932–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Loureiro-Silva MR, Cadelina GW, Iwakiri Y, Groszmann RJ. A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. J Hepatol. 2003;39:940–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Yu Q, Shao R, Qian HS, George SE, Rockey DC. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest. 2000;105:741–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Van de Casteele M, Omasta A, Janssens S et al. In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats. Gut. 2002;51:440–5.PubMedCrossRefGoogle Scholar
  48. 48.
    Van de CM, Van Pelt JF, Nevens F, Fevery J, Reichen J. Low NO bioavailability in CC14 cirrhotic rat livers might result from low NO synthesis combined with decreased superoxide dismutase activity allowing superoxide-mediated NO breakdown: a comparison of two portal hypertensive rat models with healthy controls. Comp Hepatol. 2003;2:2.CrossRefGoogle Scholar
  49. 49.
    Zafra C, Abraldes J, Turnes J et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology. 2004;126:749–55.PubMedCrossRefGoogle Scholar
  50. 50.
    Stanley AJ, Therapondos G, Helmy A, Hayes PC. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. J Hepatol. 1999;30:479–84.PubMedCrossRefGoogle Scholar
  51. 51.
    Banares R, Moitinho E, Piqueras B et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha-1 adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology. 1999;30:79–83.PubMedCrossRefGoogle Scholar
  52. 52.
    Tripathi D, Therapondos G, Lui HF, Stanley AJ, Hayes PC. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension. Aliment Pharmacol Ther. 2002;16:373–80.PubMedCrossRefGoogle Scholar
  53. 53.
    Banares R, Moitinho E, Piqueras B et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology. 2002;36:1367–73.PubMedGoogle Scholar
  54. 54.
    Bosch J, Arroyo V, Betriu A et al. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology. 1980;78:92–9.PubMedGoogle Scholar
  55. 55.
    Ballet F, Chretien Y, Rey C et al. Differential response of normal and cirrhotic liver to vasoactive agents. A study in the isolated perfused rat liver. J Pharmacol Exp Ther. 1988;244:233–5.Google Scholar
  56. 56.
    Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. N Engl J Med. 2000;342:1350–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med. 1996;25:1649–54.Google Scholar
  58. 58.
    Schneider AW, Friedrich J, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology. 1999;29:334–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Gonzalez-Abraldes J, Albillos A, Banares R et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology. 2001;121:382–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Schepke M, Werner E, Biecker E et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology. 2001;121:389–95.PubMedCrossRefGoogle Scholar
  61. 61.
    Venon WD, Baronio M, Leone N et al. Effects of long-term irbesartan in reducing portal pressure in cirrhotic patients: comparison with propranolol in a randomised controlled study. J Hepatol. 2003;38:455–60.PubMedCrossRefGoogle Scholar
  62. 62.
    Debernardi-Venon W, Barletti C, Alessandria C et al. Efficacy of irbesartan, a receptor selective antagonist of angiotensin II, in reducing portal hypertension. Dig Dis Sci. 2002;47:401–4.PubMedCrossRefGoogle Scholar
  63. 63.
    De BK, Bandyopadhyay K, Das TK et al. Portal pressure response to losartan compared with propranolol in patients with cirrhosis. Am J Gastroenterol. 2003;98:1371–6.PubMedCrossRefGoogle Scholar
  64. 64.
    Rockey DC, Fouassier L, Chung JJ et al. Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology. 1998;27:472–80.PubMedCrossRefGoogle Scholar
  65. 65.
    Leivas A, Jimenez W, Bruix J et al. Gene expression of endothelin-1 and ET(A) and ET(B) receptors in human cirrhosis: relationship with hepatic hemodynamics. J Vasc Res. 1998;35:186–93.PubMedCrossRefGoogle Scholar
  66. 66.
    Reichen J, Gerbes AL, Steiner MJ, Sagesser H, Clozel M. The effect of endothelin and its antagonist bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J Hepatol. 1998;28: 1020–30.PubMedCrossRefGoogle Scholar
  67. 67.
    Sogni P, Moreau R, Gomola A et al. Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats. Hepatology. 1998;28:655–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Poo JL, Jimenez W, Munoz R el al. Chronic blockade of endothelin receptors in cirrhotic rats: hepatic and hemodynamic effects. Gastroenterology. 1999;116:161–7.PubMedCrossRefGoogle Scholar
  69. 69.
    Cho JJ, Hocher B, Herbst H et al. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology. 2000;118:1169–78.PubMedCrossRefGoogle Scholar
  70. 70.
    Kojima H, Sakurai S, Kuriyama S et al. Endothelin-1 plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with subtype A in vivo. J Hepatol. 2001;34:805–11.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2004

Authors and Affiliations

  • Agustín Albillos
    • 1
  1. 1.Department of GastroenterologyHospital Universitario Ramón y Cajal University of AlcaláMadridSpain

Personalised recommendations